T he lymphatic vasculature forms a network of vessels that drain interstitial fluid from tissues and return this fluid to the blood. Lymphangiogesis, the formation of lymphatic vessels from preexisting lymphatic vessels, plays an important role in homeostasis of interstitial fluids, metabolism, and immunity. Recent evidence, however, indicates that lymphangiogenesis, similar to angiogenesis, also occurs during certain inflammatory and autoimmune conditions. Psoriasis, a chronic inflammatory skin disease, is characterized by extensive lymphangiogenesis, 1 and lymphatic hyperplasia is frequently observed in rejected renal transplants from patients with this condition. 2, 3 Furthermore, bacterial infection of the airway epithelia of mice induced intense lymphangiogenesis and upregulated vascular endothelial growth factors (VEGF)-C and VEGF-D. 4 After inflammation has been resolved, new lymphatic networks form a drainage system for fluid and immune cells. This system can then accelerate the inflammatory response in subsequent episodes.
Inflammation is a local protective response to harmful stimuli. During chronic inflammation, angiogenesis is induced by a variety of inflammatory mediators such as arachidonic acid metabolites, prostaglandins (PGs), 5, 6 and leukotrienes. 7 Angiogenesis is an indispensable contributor to tumor growth, and cyclooxygenase-2 (COX-2)-derived PGs play significant roles in the enhancement of tumor-associated angiogenesis, which occurs predominantly in tumor stromal tissues. We previously reported that chronic proliferative inflammation can mimic a tumor stromal reaction and that angiogenesis is highly dependent on a potent proangiogenic factor known as VEGF-A. In both inflammatory and tumor models, COX-2 derived PGE 2 exerts proangiogenic activity via EP3 signaling, with the concomitant induction of VEGF-A. Our previous studies demonstrated that VEGF-A is mainly synthesized in fibroblasts, which are major component of stromal tissues. Taken together, these findings indicate that COX-2-derived PGE 2 may exert proangiogenic effects in vivo by upregulating VEGF-A and, furthermore, that angiogenesis is controlled by nonsteroidal antiinflammatory drugs (eg, COX-2 inhibitors). However, it remains unknown whether endogenous PGE 2 enhances lymphangiogenesis during chronic proliferative inflammation or tumor development and which PGE receptors are responsible for lymphangiogenesis.
The discovery of VEGFs and their receptors has led to a better understanding of the development and function of the vasculature. 8 -10 In particular, previous studies have shown that VEGF-C and VEGF-D are primary lymphangiogenic factors that induce the growth of lymphatic vessels. 11 Fulllength VEGF-C and VEGF-D preferentially bind to VEGF receptor-3 (VEGFR-3) on lymphatic endothelial cells to induce lymphangiogenesis. Furthermore, the recent discovery of lymphatic endothelium-specific markers (eg, LYVE-1, podoplanin, Prox-1, and VEGFR-3) has allowed for more precise biological studies of the lymphatic vasculature. 8 It was previously reported that proinflammatory cytokines interleukin-1␤ and tumor necrosis factor-␣ can upregulate VEGF-C expression, 12 suggesting that inflammation may enhance lymphangiogenesis via the induction of VEGF-C.
Here, we assessed lymphangiogenesis, as well as COX-2 and Microsomal PGE synthase-1 (mPGES-1) expression, in proliferative granulation tissues that developed around subcutaneous Matrigel plugs implanted in mice. In addition, we assessed the function of EP signaling in lymphangiogenesis using PGE 2 analogues and EP receptor-knockout mice. Our findings reveal the EP receptor subtype responsible for facilitating lymphangiogenesis. Furthermore, we demonstrate that PGE 2 -EP3/4 signaling within fibroblasts and macrophages induces potent lymphangiogenic growth factors (ie, VEGF-C and VEGF-D). Thus, EP3/EP4-modulating factors are promising molecular targets for controlling lymphangiogenesis in patients with various diseases including inflammation.
Materials and Methods

Animals
Male C57/BL6 mice (8 to 10 weeks old) weighing 20 to 25 g were obtained from CLEA Japan Inc (Tokyo, Japan). PGE receptor knockout mice, EP1, EP2, EP3, or EP4 knockout mice (EP1Ϫ/Ϫ, EP2Ϫ/Ϫ, EP3Ϫ/Ϫ, EP4Ϫ/Ϫ, respectively), were obtained as previously described. [13] [14] [15] All procedures were performed in accordance with the guidelines for animal experiments established by the Kitasato University School of Medicine.
Matrigel Plug Assay
Mice were anesthetized and subcutaneously injected with phenol red-free Matrigel (BD Biosciences) containing fibroblast growth factor-2 (FGF-2) (125 ng/site, Peprotech EC). Saline-containing Matrigel served as vehicle control. A COX-2 inhibitor (celecoxib) was orally administrated daily (10, 30, or 100 mg/kg). In another experiment, mice were injected with Matrigel containing FGF-2 (50 ng/site). After 4 days, these mice received topical PG (PGE 2 , 10 nmol/plug per day, once a day for 3 days). After a certain period of feeding, mice were euthanized, and the Matrigel plugs were dissected. The plugs were either processed for immunocytochemistry or analyzed via real-time quantitative reverse transcription-polymerase chain reaction (RT-PCR).
Real-Time Quantitative RT-PCR
The quantitative real-time RT-PCR of total RNA isolated from Matrigels was performed with appropriate primers as described in the Supplemental Materials, available online at http://atvb. ahajournals.org.
Drainage of Fluorescein Isothiocyanate-Dextran From the Matrigels
Drainage of the dye via the lymphatics was assayed as described in the Supplemental Materials.
Immunohistochemistry
For immunohistochemistry, the primary antibodies used were antimouse podoplanin ( 
Statistical Analysis
Data were expressed as meansϮSEM. Comparisons of multiple groups were performed by factorial analysis of variance (ANOVA), followed by the Scheffe test. Comparisons between 2 groups were performed by Student t tests. Probability values Ͻ0.05 were considered statistically significant.
Results
Lymphangiogenesis in Proliferative Granulation Tissues and Suppression of Lymphangiogenesis by a COX-2 Inhibitor
To evaluate lymphangiogenesis in proliferative granulation tissues, we injected Matrigel plugs containing FGF-2 (125 ng/site) into the subcutaneous tissues of mice, thereby inducing the formation of granulation tissues around and in the Matrigels. In the absence of FGF-2, VEGFR-3 expression remained virtually unchanged on days 4, 7, 10, and 14. Meanwhile, FGF-2 stimulation significantly enhanced VEGFR-3 expression in granulation tissues on days 7, 10, and 14 ( Figure 1A) .
To determine whether COX-2 enhances lymphangiogenesis, we examined the effects of a selective COX-2 inhibitor (celecoxib) on lymphangiogenesis. When celecoxib was administered orally (10, 30, or 100 mg/kg) in conjunction with FGF-2, the expression of VEGFR-3 mRNA was reduced in a dose-dependent manner in granulation tissues on day 7 and was significantly inhibited at a 100 mg/kg dose, which resulted in mRNA levels similar to those observed in mice without FGF-2 treatment ( Figure 1B) .
When the distribution of lymphatic vessels in granulation tissues was analyzed at day 14 by immunostaining for podoplanin, the lymphatic-like structures positive for the podoplanin antibody were observed in the granulation tissues formed around the Matrigel plugs (Figure 2A , red arrow- heads). Addition of FGF-2 to the gel resulted in an increase in the tube formation of lymphatics ( Figure 2A ). Celecoxib administration (100 mg/kg) reduced the tube formation of lymphatics enhanced by FGF-2 ( Figure 2A ). When we further performed double immunostainings of the lymphatic-specific markers LYVE-1 and VEGFR-3 on day 14, it was revealed that the penetration of LYVE-1 and VEGFR-3 doublepositive lymphatic vessels into Matrigel was increased with FGF-2 stimulation ( Figure 2B , white arrows), whereas administration of celecoxib significantly reduced LYVE-1 and VEGFR-3 double-positive lymphatic vessel formation (Figure 2B ). The formation of lymphatic-like structures was accompanied by the infiltration of LYVE-1 and VEGFR-3 double-positive macrophage-like cells ( Figure 2B , white asterisks) into the granulation tissues. The density of doublepositive cells was apparently increased with FGF-2, but it was reduced with concomitant administration of celecoxib. Computer-assisted morphometric analysis confirmed that the relative area occupied by lymphatic-like vessels (LYVE-1 and VEGFR-3 double-positive) was strongly increased in Matrigels with FGF-2, but it was significantly inhibited by administration of celecoxib, which resulted in levels similar to those observed in Matrigels without FGF-2 treatment ( Figure 2B and 2C) . To test whether COX-2 inhibition suppresses lymphangiogenic macrophage infiltration, we investigated the number of macrophages in FGF-2-implanted Matrigel with or without celecoxib treatment. We detected a decrease in macrophage infiltration with celecoxib treatment ( Figure 2D ).
In addition, as shown in Figure 2E , the drainage of fluorescence dye from the Matrigel interior was reduced with a COX-2 inhibitor. These results suggest that lymphangiogenesis modulates lymphatic flow in newly formed lymphatic vessels via a COX-2-dependent mechanism. Taken together, these results suggest that COX-2 upregulates lymphangiogenesis.
Role of COX-2-and mPGES-1-Derived PGE 2 in Enhancement of Lymphangiogenesis and VEGF-C/VEGF-D Expression
On day 4, FGF-2 stimulation markedly enhanced COX-2 and mPGES-1 mRNA expression in granulation tissues ( Figure 3A and 3B). Immunohistochemical analyses revealed an increase of the granulation tissue area in response to FGF-2 stimulation, and COX-2 and mPGES-1 expression in these proliferative granulation tissues ( Figure 3C ). To identify the PG species generated through the actions of COX-2 and mPGES-1, PGE 2 (10 nmol/ plug per day, once a day for 3 days) was topically injected into the granulation tissues around and in the Matrigels with FGF-2 (50 ng/site). When we performed immunostaining for podoplanin, it revealed that the lymphatic-like structures positive for the podoplanin antibody were observed in the granulation tissues around the Matrigel plugs with topical injection of PGE 2 ( Figure  4A , red arrows). The expression of VEGFR-3 was also markedly enhanced in response to stimulation of PGE 2 (Figure 4A ). Furthermore, we detected an increased amount of VEGF-C and VEGF-D in response to PGE 2 treatment ( Figure 4B and 4C) . Thus, topical injection of PGE 2 markedly increased VEGFR-3 expression, suggesting that COX-2-and mPGES-1-generated PGE 2 facilitates lymphangiogenesis by inducing VEGF-C and VEGF-D.
Reduced Lymphangiogenesis in EP3 and EP4 Receptor Knockout Mice
To identify the receptors of COX-2-derived PGs that are responsible for enhancing lymphangiogenesis, we evaluated the expression of VEGFR-3 during lymphangiogenesis in mice lacking EP1, EP2, EP3, and EP4. Stimulation of lymphangiogenesis with FGF-2 (125 ng/site) did not modulate VEGFR-3 expression in EP1Ϫ/Ϫ and EP2Ϫ/Ϫ mice relative to wild-type (WT) mice ( Figure 5A ). In contrast, VEGFR-3 expression was significantly lower in EP3Ϫ/Ϫ and EP4Ϫ/Ϫ mice compared with WT mice ( Figure 5A ). When the distribution of lymphatic vessels in granulation tissues was analyzed by immunostaining for the lymphatic-specific markers LYVE-1 and VEGFR-3, it was revealed that LYVE-1 and VEGFR-3 positive lymphatic vessels penetrated into Matrigels were suppressed in EP3Ϫ/Ϫ and EP4Ϫ/Ϫ mice ( Figure 5B to 5E ). Computer-assisted morphometric analysis also proved that the relative area occupied by lymphatic vessels (LYVE-1 and VEGFR-3 double-positive) was significantly suppressed in EP3Ϫ/Ϫ and EP4Ϫ/Ϫ mice compared with WT mice (Figure 5C and 5E ). When macrophage population was determined by CD11b antibody, the decreased macrophage infiltration in EP3Ϫ/Ϫ and EP4Ϫ/Ϫ mice was observed in comparison with that in WT mice ( Figure 5F and 5G) . These results suggest that lymphangiogenesis in granulation tissues depends on endogenous PGE 2 and EP3/EP4 receptor signaling.
Identification of EP Receptor Signals That Induce VEGF-C and VEGF-D Expression in Fibroblasts and Macrophages In Vitro
We characterized the major components of the granulation tissues (ie, fibroblasts and macrophages) with Mac-1/CD3e double-negative and Mac-1 positive, respectively. Thus, we tested which EP receptor subtypes upregulate the expression of VEGF-C and VEGF-D in fibroblasts and macrophages in vitro. When mouse fibroblasts (L929 cells) were treated with highly selective EP agonists, VEGF-D expression but not VEGF-C expression increased in a dose-dependent manner in response to PGE 2 and an EP4 agonist (ONO-AEI-329) ( Figure 6A ). However, VEGF-C expression increased in macrophages isolated from the peritoneal cavities of WT mice in response to PGE 2 stimulation with an EP3 agonist (ONO-AE-248) and an EP4 agonist ( Figure 6B ). Furthermore, VEGF-D expression increased in response to an EP3 agonist ( Figure 6C ). Neither the EP1 agonist (ONO-DI-004) nor the EP2 agonist (ONO-AE1-259-01) significantly enhanced VEGF-C and VEGF-D production in L929 cells and macrophages ( Figure 6A to 6C) .
Furthermore, the expression of VEGF-C, VEGF-D, and COX-2 in macrophages and fibroblasts was confirmed in vivo in FGF-2-implanted Matrigel by immunostaining (Figure 6D) . On day 4, cells positive for S100A4, an activated fibroblast maker, only slightly expressed VEGF-C but were positive for VEGF-D. By contrast, CD11b-positive cells expressed both VEGF-C and VEGF-D. COX-2 expression was detected both in fibroblasts and macrophages.
These results, taken together, suggest that endogenous PGE 2 upregulates VEGF-C and VEGF-D production; that EP3 signaling increases VEGF-C and VEGF-D expression, predominantly in macrophages; and that EP4 signaling increases VEGF-C expression in macrophages and VEGF-D expression in fibroblasts. Thus, endogenous PGE 2 appears to regulate lymphangiogenesis differently in response to cell type.
Discussion
The lymphatic system plays an important role in immune surveillance, tissue fluid homeostasis, and fat absorption. 16 Similar to angiogenesis, lymphangiogenesis has also been implicated in a number of pathological conditions, including neoplasm metastasis, edema formation, impaired wound healing, and various inflammatory diseases. 7, 17, 18 Angiogenesis and lymphangiogenesis are tightly regulated by several key growth factors and cytokines. Several factors (eg, FGF-2, VEGF, platelet-derived growth factor, and angiopoietin families) modulate the growth of blood and lymphatic vessels, and to stimulate lymphangiogenesis, 19 -22 we used FGF-2 in the present experiment. Furthermore, several reports demonstrated that PGs, which are enzymatically derived from arachidonic acid, exhibit proangiogenic activity. [23] [24] [25] [26] Thus, future therapeutic strategies may involve controlling PG formation and receptor signaling. [27] [28] [29] However, the roles of PGs in lymphangiogenesis remain not fully clarified. 30 In the present study, we used Matrigel plugs to evaluate lymphangiogenesis during development of proliferative granulation tissues around the gels, although this Matrigel model was used for the evaluation of angiogenesis and cell migration assays. We have a strong interest in lymphangiogenesis during development of chronic inflammation, and we repeatedly used the surgical sponge implantation models that allow us to analyze the pro-and antiangiogenic activities. In the sponge model, granulation tissues with the property of chronic inflammation were formed around the sponge implants with enough reproducibility, and we can easily determine the active molecules at the site of the chronic inflammation, because rapid sampling and easy extractions of active molecules and mRNA can be performed in the sponge model. The results with this sponge model have been published in some journals, 5, 6, 26, 27, 29, [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] and many researchers have a strong interest in this model. In the beginning of this study, we had tried to test this sponge model to clarify the involvement of PGs in lymphangiogenesis during the chronic inflammation, but the detection of newly developed lymphatics was quite difficult in the sponge model. We hypothesized that the surgical procedure to implant the sponges may hamper the observation of lymphangiogenesis that may be derived from the preexisting lymphatics.
When we implanted the Matrigel in the subcutaneous tissues of mice using fine needles with syringes containing Matrigel, we could observe lymphangiogenesis in the granulation tissues formed around the gel, as determined by podoplanin immunohistochemistry and LYVE-1/VEGFR-3 double immunostaining. Although the thickness of the granulation tissues was thin in the Matrigel model in comparison with that in sponge model, highly reproducible granulation tissue formation was seen in the Matrigel model. In the preliminary experiment, we topically injected FGF-2 into the gel to enhance the formation of granulation tissues with enough reproducibility. We had previously reported that FGF-2 application to the sponge implants enhanced angiogenesis, together with inductions of COX-2 and VEGF-A. 6 VEGF-A is known to enhance lymphangiogenesis. 41 Furthermore, FGF-2 is also reported to enhance lymphangiogenesis. 20 -22 Thus, FGF-2 stimulation is quite reasonable stimula-tion to see lymphangiogenesis in the Matrigel model. In fact, we can see enhanced lymphangiogenesis with FGF-2 in the granulation tissues around the gel when estimated with VEGFR-3 expression, VEGFR-3/LYVE-1 double immunostaining, and podoplanin immunohistochemistry (Figures 1 and 2) . The enhanced prolymphangiogenic responses were strongly suppressed with the COX-2 inhibitor celecoxib ( Figure 2 ).
Furthermore, this Matrigel model was quite suitable to evaluate the interplay between the newly formed lymphatics and the hematopoietic and inflammatory cells, such as macrophages possibly recruited from the bone marrow. It was frequently reported that macrophages positive for LYVE-1 influence lymphangiogenesis. [41] [42] [43] [44] [45] [46] In fact, we observed that the macrophage-like cells positive for LYVE-1 and VEGFR-3 accumulated to the granulation tissues. Further-more, it was reported that VEGFR-1 tyrosine kinase signaling promotes lymphangiogenesis, as well as angiogenesis, indirectly via macrophage recruitment. 47 This model is a useful one because of the easy procedure to test lymphangiogenesis with high reproducibility.
Previous studies have shown that PGs are produced following the sequential oxidation of arachidonic acid by COX and terminal PG synthases. During inflammation, the expression of PGs such as PGE 2 and PGI 2 is increased by COX-2. Although previous studies have suppressed lymphangiogenesis and lymph node metastasis by inhibiting COX-2, 48, 49 we present the first evidence that COX-2 inhibitors also suppress lymphangiogenesis in chronic inflammatory granulation tissues. Our results suggest that COX-2 contributes to the regulation of lymphangiogenesis. Proinflammatory stimuli are known to induce mPGES-1, which promotes the production of PGE 2 via a coupling reaction with COX-2. 50 Here, we observed the simultaneous expression of mPGES-1 and COX-2 and therefore speculated that PGE 2 might be associated with lymphangiogenesis. In fact, lymphangiogenesis was induced within granulation tissues in response to PGE 2 . Furthermore, when the proliferative granulation tissues were reinforced using FGF-2, expression of VEGFR-3, VEGF-C, and VEGF-D was markedly enhanced. These findings suggest that PGE 2 is involved in inflammation-mediated lymphangiogenesis and that the formation of granulation tissue in chronic inflammatory lesions plays an important role in lymphangiogenesis.
PGs exert their biological effects by binding to specific receptors that contain 7 transmembrane domains. Previous studies have identified and cloned PGE receptors, including 4 subtypes (ie, EP1, EP2, EP3, and EP4). 51 The genes encoding each of these receptors have been disrupted and corresponding knockouts have been produced in mice. 14, 27, 28, 33, [52] [53] [54] [55] [56] Furthermore, highly selective agonists and antagonists for each of the 4 EP subtypes have been developed using cloned receptors. [57] [58] [59] In vitro studies of cancer cell lines revealed that PGE 2 receptors mediate the upregulation of VEGF-C. 15, 60 However, no studies have verified these findings in host cells. On the other hand, macrophages are recruited into inflammatory lesions, where they secrete VEGF-C and contribute to lymphangiogenesis. 4, 46 In the present study, we clarified the role of PGE 2 -EP receptor signaling in lymphangiogenesis using an in vivo Matrigel assay in 4 subtypes of EP receptor knockout mice, as well as WT mice. In addition, we performed in vitro experiments using fibroblasts and macrophages (ie, cells that are found in granulation tissues).
In the presence of FGF-2, the expression of VEGFR-3 in granulation tissues was markedly reduced in EP3Ϫ/Ϫ and EP4Ϫ/Ϫ mice compared with WT mice ( Figure 5 ). In mouse fibroblasts and macrophages, activation of the EP3 and EP4 receptors enhanced expression of VEGF-C and VEGF-D ( Figure 6 ). These findings suggest that EP3 and EP4 receptor signaling enhances lymphangiogenesis during chronic inflammation via the induction of VEGF-C and VEGF-D. Lymphatics formed in the granulation tissues around and in the Matrigels may play an active role in this process, as dye drainage from the lymphatics was suppressed in the presence of a COX-2 inhibitor ( Figure 2C) . These results suggest that endogenous PGs regulate the generation of functionally active lymphatics and that selective inhibition of EP signaling may counteract edema formation in patients with proliferative inflammatory conditions. In our previous report, we had observed that COX-2-derived PGs enhanced tumorassociated lymphangiogenesis, because a COX-2 inhibitor, celecoxib, inhibited the expression of VEGFR-3 and the formation of vessel structures positive for podoplanin. 30 Interestingly, we obtained conflicting results when VEGF isoforms were induced in fibroblasts and macrophages (Figure 6 ). Inflammatory cytokines upregulate VEGF-C and VEGF-D, although the pathophysiological significance of these inductions remains unclear. In vitro studies have shown that proinflammatory cytokines (eg, interleukin-1␤, tumor necrosis factor-␣, phorbol esters and growth factors) can stimulate vegf-C expression in several types of cells, including fibroblasts and cancer cells. 12, [61] [62] [63] An inflammatory cytokine (ie, tumor necrosis factor-␣) stimulated VEGF-C expression in CD11b ϩ osteoclast precursors and increased nuclear factor-B binding to a nuclear factor-B sequence in the VEGF-C promoter. 64 We found that VEGF-D expression but not VEGF-C expression was markedly enhanced in fibroblasts in response to an EP4 receptor agonist but not in response to EP1, EP2, and EP3 receptor agonists ( Figure 6 ). None of the PGE 2 agonists and all of the EP receptor agonists significantly enhanced VEGF-C expression. These observations suggest that VEGF-C expression is finely controlled in different cell types. However, the EP3 receptor agonist markedly enhanced VEGF-C and VEGF-D expression in macrophages, and the EP4 receptor agonist enhanced expression of VEGF-C. Few studies have examined VEGF-C induction, although Vegf-D expression is known to be induced by cell-cell contact mediated by cadherin-11. 62 Sequences upstream of the VEGF-C translation start site were found to contain consensus binding sites for the AP-2 transcription factor, suggesting that the cAMP-dependent protein kinase activates the AP-2 transcription factor to regulate VEGF-C transcription. 13, 65 The transcription factors and regulatory promoter elements controlling vegf-D gene expression have not yet been identified; however, previous studies have suggested that AP-1 directly regulates vegf-D expression, as human vegf-D cDNA was initially isolated using an AP-1 overexpression strategy. 66 We previously reported that EP3 signaling activates AP-1 in fibroblasts. 27 It has also been established that EP4 and a splicing variant of EP3 can activate adenylate cyclase, thereby elevating cAMP levels. These findings suggest that PGE 2 regulates lymphangiogenesis in a cell-specific manner.
In conclusion, lymphangiogenesis may be upregulated by endogenous PGs derived from COX-2 in the proliferative inflammation. Signaling by EP3 and EP4 promotes lymphangiogenesis in proliferative inflammation and upregulates VEGF-C and VEGF-D expression in fibroblasts and macrophages ( Figure 6 ). Furthermore, newly formed lymphatics drain interstitial fluids in inflammatory sites via a COX-2dependent mechanism. Our findings indicate that therapeutic modalities should target COX-2 and EP3/4 receptor signaling to prevent lymphangiogenesis.
